Drug Profile
LY 316108
Alternative Names: NNC 112192Latest Information Update: 09 Feb 2000
Price :
$50
*
At a glance
- Originator Eli Lilly and Company; Novo Nordisk
- Developer Eli Lilly; Eli Lilly and Company; Novo Nordisk
- Class Analgesics; Irritable bowel syndrome therapies; Small molecules
- Mechanism of Action Muscarinic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Irritable bowel syndrome; Pain
Most Recent Events
- 09 Feb 2000 No-Development-Reported for Irritable bowel syndrome in Denmark (PO)
- 09 Feb 2000 No-Development-Reported for Irritable bowel syndrome in USA (PO)
- 09 Feb 2000 No-Development-Reported for Pain in Denmark (PO)